ArticleBMC geriatrics2026
Association of 90-day post-transplant low magnesium exposure with new-onset post-transplant diabetes mellitus in older kidney transplant recipients.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPost‑transplantation diabetes mellitus (PTDM) is common after kidney transplantation, and older recipients are particularly vulnerable. Hypomagnesemia occurs frequently early after transplantation, but whether persistently low serum magnesium in the first 90 days is associated with subsequent PTDM is unclear.
methodsWe conducted a single‑center ambispective cohort study of kidney‑only recipients aged ≥ 65 years transplanted between January 2014 and June 2024, using a prespecified day‑90 landmark. Serum magnesium measured during post‑transplant days 0-90 was summarized as a time‑weighted average (TWA‑Mg90) using trapezoidal integration. Low magnesium exposure was defined as TWA‑Mg90 below the laboratory lower limit of normal (LLN; 0.72 mmol/L). PTDM was adjudicated using standard venous plasma glucose criteria. Diabetic‑range glycemia in days 0-45 was classified as early post‑transplant hyperglycemia rather than PTDM. Adjusted cause‑specific Cox models including baseline metabolic risk, immunosuppression, day-90 kidney function, and transplant year estimated adjusted hazard ratio (aHR) of incident PTDM after day 90. Modified Poisson regression estimated adjusted risk ratios (aRR) for PTDM occurring between day 90 and day 365.
resultsOf 742 screened recipients, 652 were eligible at day 90. After excluding 61 PTDM cases on days 46-90, 591 entered the landmark cohort. Magnesium was measured a median of 9 times during days 0-90, and 306/591 (51.8%) had low magnesium exposure. After day 90, 160/591 (27.1%) developed PTDM (138 by day 365). Low magnesium exposure was associated with higher PTDM hazard (aHR 1.52, 95% CI 1.14-2.03; p = 0.004) and higher day 90-365 risk (aRR 1.23, 95% CI 1.05-1.44). Each 0.1 mmol/L lower TWA‑Mg90 was associated with increased PTDM hazard (aHR 1.19, 95% CI 1.05-1.35), with no strong evidence of nonlinearity (p = 0.21).
conclusionsIn older kidney transplant recipients, a higher persistent low‑magnesium during days 0-90 was associated with later PTDM. Because magnesium is routinely monitored after transplantation, sustained early hypomagnesemia may serve as a pragmatic risk marker to support targeted, guideline-consistent glycemic assessment within routine follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.